These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 14997414)

  • 1. [PSA related screening of prostate cancer. Panic or improvement?].
    Fornara P; Jurczok A
    Aktuelle Urol; 2004 Feb; 35(1):43-8. PubMed ID: 14997414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
    Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mass screening for prostate cancer is the best approach to early diagnosis and treatment of prostate cancer].
    Zhao XJ; Kong XB; Wang WH
    Zhonghua Nan Ke Xue; 2003 Nov; 9(8):563-5, 568. PubMed ID: 14689882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diagnosis of cancer of the prostate (I): Advancements in knowledge and practice since the consensus conference of 1989. The "Cancer of the Prostate" subcommittee of the Committee of Oncology of the French Association of Urology].
    Villers A; Grosclaude P; Haillot O; Abbou CC; Richard F; Boccon-Gibod L
    Prog Urol; 1997 Jun; 7(3):508-15. PubMed ID: 9273082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker.
    Hernández J; Thompson IM
    Cancer; 2004 Sep; 101(5):894-904. PubMed ID: 15329895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is prostate-specific antigen still the best tumor marker for prostate cancer?
    Leewansangtong S; Soontrapa S; Tantiwong A
    J Med Assoc Thai; 1999 Oct; 82(10):1034-40. PubMed ID: 10561969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Screening for prostate cancer--what does the evidence show?].
    Borre M; Iversen P
    Ugeskr Laeger; 2007 May; 169(20):1887-8. PubMed ID: 17553362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
    Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Advancements in PSA-based screening for prostate cancer].
    Ito K
    Rinsho Byori; 2004 Jul; 52(7):611-7. PubMed ID: 15344561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Schröder FH; Raaijmakers R; Postma R; van der Kwast TH; Roobol MJ
    J Urol; 2005 Aug; 174(2):489-94; discussion 493-4. PubMed ID: 16006878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ; Roobol DW; Schröder FH
    Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of PSA screening. Early detection of prostate cancer.
    Pickles T
    Can Fam Physician; 2004 Jan; 50():57-63. PubMed ID: 14761105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
    Roobol MJ; Grenabo A; Schröder FH; Hugosson J
    J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later.
    Pienta KJ
    Urology; 2009 May; 73(5 Suppl):S11-20. PubMed ID: 19375622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Early detection of cancer of the prostate. Pros and cons].
    Hoesl CE; Altwein JE
    MMW Fortschr Med; 2005 Apr; 147(14):32, 34-6. PubMed ID: 15887681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rural residence and prostate cancer screening with prostate-specific antigen.
    Stamatiou K; Skolarikos A
    Rural Remote Health; 2009; 9(2):1227. PubMed ID: 19594290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence.
    Etzioni RD; Ankerst DP; Weiss NS; Inoue LY; Thompson IM
    J Natl Cancer Inst; 2007 Oct; 99(20):1510-5. PubMed ID: 17925534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early diagnosis of prostate cancer: the continuing debate on the impact on mortality.
    Höltl W; Lunglmayr G
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):440-1. PubMed ID: 16091868
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.